#ASH22: ALX Oncology reports complete response with anti-CD47 candidate in combo trial
NEW ORLEANS — ALX Oncology said it’s getting some promising, if very early, signals from a small trial that could give its CD47 drug new life …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
